Welcome to our dedicated page for Generate Biomedicines news (Ticker: GENB), a resource for investors and traders seeking the latest updates and insights on Generate Biomedicines stock.
Generate Biomedicines, Inc. reports news tied to its clinical-stage biotechnology pipeline, generative biology platform, and public-company disclosures. Recurring updates cover financial results, business updates, clinical program progress for GB-0895, GB-4362, and GB-5267, regulatory designations, and collaborations connected to its protein therapeutic candidates.
Company news also includes shareholder voting matters, capital-structure disclosures, and clinical or regulatory disclosures following its transition to a Nasdaq-listed public company.
Generate Biomedicines (GENB)/b) will participate in multiple healthcare investor conferences in New York in September 2026.Management presentations are scheduled at the Cantor Global Healthcare Conference on September 9 at 3:55 p.m. ET, the Morgan Stanley 24th Annual Global Healthcare Conference on September 14 at 7:00 a.m. ET, the Goldman Sachs Life Sciences Symposium on September 15 at 9:05 a.m. ET, the H.C. Wainwright 28th Annual Global Investment Conference on September 16 at 10:30 a.m. ET, and Bernstein Insights Healthcare Leaders and Disruptors on September 23 at 8:00 a.m. ET.
Live webcasts and 90‑day replays will be available via the Investors “Events & Presentations” page on the company’s website, which, along with its LinkedIn and X accounts, may be used for material disclosures.
Generate Biomedicines (NASDAQ: GENB) reported Q2 2026 collaboration revenue of $6.3 million, down from $10.1 million a year earlier, and a net loss of $67.3 million versus $56.7 million. Cash, cash equivalents, and marketable securities totaled $457.4 million as of June 30, 2026, which the company believes will fund its current operating plan into the first half of 2028.
Clinical progress included advancing global Phase 3 SOLAIRIA-1 and SOLAIRIA-2 trials of GB-0895 in severe asthma, Phase 1b COPD data and asthma data to be presented at ERS 2026, and enrollment of the first cohort in the Phase 1 study of GB-4362, an FDA Fast Track MMAE neutralizer. Novartis moved an AI-designed biologic from The Generate Platform into its preclinical pipeline, and a Phase 1 trial of GB-5267 CAR T in ovarian cancer is recruiting.
AdvanCell signed a long-term lease for the entire ~128,000 square foot 1 Corporate Drive building at IQHQ's Innovation Park in Andover, Massachusetts, bringing newly constructed Phase 2 to 100% leased. The 340,000 square foot campus hosts advanced life science manufacturing, amenities, and infrastructure.
AdvanCell, a clinical-stage radiopharmaceutical company, will use the site as its global headquarters and first U.S. manufacturing facility to scale Lead-212 targeted alpha therapy production, including lead candidate 212Pb-ADVC001 for prostate cancer. Innovation Park also includes Generate Biomedicines (NASDAQ: GENB), which completed a ~$400 million IPO in February 2026.
Generate Biomedicines (NASDAQ: GENB) plans to participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026.
A live webcast and an archived replay are expected to be available on the company’s investor website under Events and Presentations.
Generate Biomedicines (NASDAQ: GENB) reported Q1 2026 results and clinical progress on May 7, 2026. Cash, cash equivalents, and marketable securities totaled $516.6M as of March 31, 2026, reflecting $369.3M net IPO proceeds. Revenue was $7.2M; net loss was $61.7M. SOLAIRIA-1 and SOLAIRIA-2 Phase 3 trials for GB-0895 continue; GB-4362 sites activated with FDA Fast Track designation and mid-2026 dosing expected; GB-5267 first dosing expected in H2 2026. Generate expects cash to fund operations into H1 2028 and may require additional capital for longer-term operations.
Generate Biomedicines (Nasdaq: GENB) priced an initial public offering of 25,000,000 shares at $16.00 per share, implying gross proceeds of $400 million before underwriting discounts and offering expenses. The underwriters have a 30‑day option for an additional 3,750,000 shares.
Generate's common stock is expected to begin trading on the Nasdaq Global Select Market on February 27, 2026, and the offering is expected to close on March 2, 2026, subject to customary closing conditions. The SEC declared the registration effective on February 26, 2026.